FIELD: medicine; pharmacology.
SUBSTANCE: invention concerns application of selective agonist of alpha-2B or alpha-2B/2C adrenoreceptors for manufacture of medical product (MP), applied for treatment of neurodegenerative cerebrum conditions. Applicability of selective agonist of alpha-2B or alpha-2B/2C adrenoreceptors as MP is first shown for diseases causing damaged neurons with endings approaching to black substance or moving away.
EFFECT: products have improved efficiency.
9 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINES IN DEMENTIA AND PARKINSON'S DISEASE TREATMENT | 2003 |
|
RU2332218C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | 2009 |
|
RU2540470C9 |
| METHOD OF ACTIVATION OF REGULATORY T-CELLS OF ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | 2011 |
|
RU2599495C2 |
| APPLICATION OF K-252A DERIVATIVES TO TREAT DISORDERS OF PERIPHERAL OR CENTRAL NERVOUS SYSTEMS AND EXCESSIVE CYTOKINE OUTPUT | 1997 |
|
RU2183959C2 |
| AGENT FOR TREATING PARKINSON'S DISEASE | 2024 |
|
RU2839611C1 |
| ACTIVE SOLUBLE ISOFORMS OF NEUREGULIN, WHICH CARRY POST-TRANSLATION MODIFICATIONS | 2008 |
|
RU2491955C2 |
| NON-SEDATIVE A-2-AGONIST 1-(2,3-DIMETHYL-PHENYL)-ETHYL-1,3-DIHYDRO-IMIDASOLE-2-THIONE | 2004 |
|
RU2345987C2 |
| SELECTIVE INVERSE SEROTONIN 2A/2C RECEPTOR AGONISTS APPLICABLES AS THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISORDERS | 2008 |
|
RU2465267C2 |
| IMPLANT FOR PROLONGED DRUG DELIVERY | 2014 |
|
RU2641021C2 |
| COMPOUNDS AND METHODS | 2015 |
|
RU2711442C2 |
